-
FDA Approves New Treatment Option: Osimertinib Plus Chemotherapy for EGFR+ NSCLC
The US Food and Drug Administration (FDA) approved a new treatment option for people diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors... -
Using T cells to Tackle Drug Resistance in EGFR+ Lung Cancer
Approximately 10%-15% of patients with non-small cell lung cancer have tumors with mutations in the EGFR (epidermal growth factor receptor) gene. EGFR mutations are known to drive... -
Fertility Preservation and Cancer
Medications and treatments for lung cancer can affect fertility in both women and men. This video covers how to work with a reproductive endocrinologist, the first steps after... -
Lung Cancer Masterclass: Get Smart About Lung Cancer
In the past five years, the lung cancer community has seen an astonishing number of new treatments. As our understanding of lung cancer has deepened, the older treatment approaches... -
Finding Balance in Life and Treatment with Marnie Clark
The symptoms that led Marnie Clark to her doctor were unusual. Her leg was feeling “weird,” but it was more of an annoyance than something she was concerned about. Then came an... -
Questions to Ask About Clinical Trials
Asking your doctor and medical team questions about clinical trials is a helpful way to decide if they are a good fit for you. You may already have some in mind, but a few basic... -
Clinical Trial Phases
The four phases of lung cancer clinical trials each serve a different and important purpose. From testing the safety of a new treatment to its effectiveness and long-term outcomes... -
Helpful Apps for People Living with Cancer
As mobile apps become more ingrained in our lives, it’s natural to look for ones that can help manage a cancer diagnosis. As for which app to choose, it really comes down to what... -
Drs. Susumu Kobayashi and Alexandre Reuben Announced as Recipients of EGFR Resisters/LUNGevity Research Award
LUNGevity Foundation is thrilled to announce the recipients of the EGFR Resisters/LUNGevity Research Award for EGFR-Positive Lung Cancer. EGFR Resisters, a vibrant patient-led... -
LUNGevity Announces $1.2M in Lung Cancer Workforce Development Research Awards
LUNGevity Foundation is proud to announce the recipients of four awards to bolster the lung cancer research workforce— the Career Development Award, the VA Research Scholar Award... -
Finding (Mental) Peace this Holiday Season
The holidays are stressful enough without having to deal with lung cancer. LUNGevity is here to help. This discussion of the mental health challenges we face in the lung cancer... -
Treatment & Research Takeaways: ESMO 2023 Meeting
The European Society for Medical Oncology (ESMO) recently held its annual conference from October 20 – 24, 2023 in Madrid, Spain. ESMO represents one of the largest gatherings of...
EGFR